Allogene Therapeutics, Inc. announced that data from its Phase 1 UNIVERSAL trial of ALLO-715, an anti-BCMA AlloCAR T product candidate for relapsed/refractory (r/r) multiple myeloma (MM) has been published in Nature Medicine. UNIVERSAL is the first and only allogeneic CAR T study to demonstrate that significant responses can be achieved with a single dose in patients with relapsed/refractory multiple myeloma. These initial study results published in Nature Medicine reinforce belief that ALLO-715 can induce deep, clinically meaningful responses in patients with an allogeneic cell therapy. The Phase 1 UNIVERSAL study is a dose escalation trial in patients with heavily pretreated r/r MM.

The Nature Medicine publication includes data from the first 48 patients enrolled with a data cutoff of October 2021. All patients treated were refractory to their last line of treatment and no bridging therapy was used in this trial. Data demonstrated the ability for an allogeneic CAR T to achieve response rates in line with certain approved autologous CAR T therapies and durable remissions with a manageable safety profile while treating 92% of all enrolled patients and all product manufactured and released as per product specifications.

Updated data from the UNIVERSAL study were presented at the Company's R&D Showcase in November 2022 and the American Society of Hematology Annual Meeting in December 2022.